Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioAtla (BCAB)
NASDAQ:BCAB
Holding BCAB?
Track your performance easily
Earnings Data
Report Date
Mar 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.39Last Year’s EPS
-$0.56Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -68.83%
|Next Earnings Date:Mar 20, 2025
Earnings Call Sentiment|Positive
The earnings call indicates significant progress in clinical trials and strategic collaborations, with promising results in key oncology programs and financial improvements. However, there are challenges in maintaining R&D spending and managing cash reserves.Company Guidance
During the BioAtla third quarter 2024 earnings call, the company provided comprehensive guidance on their clinical programs and financial performance. Key metrics from their clinical trials included the CAB-ROR2-ADC ozuriftamab vedotin monotherapy for head and neck cancer, showing a median duration of response of 4.4 months and an overall survival of approximately 9 months. The CAB-CTLA-4 antibody evalstotug for melanoma achieved tumor reduction in all 8 patients, with 4 responders, including 1 complete response. Additionally, the CAB-AXL-ADC mecbotamab vedotin showed a median overall survival of 12.6 months for patients with mutant KRAS variants. Financially, BioAtla reported a net loss of $10.6 million for Q3 2024, compared to $33.3 million in Q3 2023, with cash and cash equivalents at $56.5 million as of September 30, 2024, projected to fund operations into early 2026.Ozuriftamab Vedotin Fast Track Designation
The CAB-ROR2-ADC ozuriftamab vedotin was granted Fast Track designation by the FDA for treating refractory head and neck cancer, showing promising median duration of response and overall survival rates.
Evalstotug Phase II Melanoma Results
All 8 patients treated with evalstotug plus PD-1 showed tumor reduction, with 4 responders including 3 partial responses and 1 complete response, indicating a potential best-in-class CTLA-4 profile.
Mecbotamab Vedotin Encouraging Findings
Observations in non-small cell lung cancer patients with MK-RAS variants show a median overall survival of 12.6 months and a manageable safety profile, suggesting a potential pan-KRAS strategy.
Financial Improvements and Collaborations
Net loss decreased significantly to $10.6 million from $33.3 million year-over-year, supported by $11 million in collaboration revenue from a worldwide license agreement with Context Therapeutics.
---
BCAB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BCAB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $2.22 | $2.10 | -5.41% |
| Aug 08, 2024 | $1.47 | $1.47 | 0.00% |
| May 14, 2024 | $2.61 | $3.00 | +14.94% |
| Mar 26, 2024 | $3.01 | $3.46 | +14.95% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does BioAtla (BCAB) report earnings?
BioAtla (BCAB) is schdueled to report earning on Mar 20, 2025, TBA Not Confirmed.
What is BioAtla (BCAB) earnings time?
BioAtla (BCAB) earnings time is at Mar 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BCAB EPS forecast?
BCAB EPS forecast for the fiscal quarter 2024 (Q4) is -$0.39.
---
